A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.

@article{Wilens2015ARP,
  title={A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.},
  author={Timothy E Wilens and Brigitte Robertson and Vanja Sikirica and Linda Harper and Joel L. Young and Ralph Bloomfield and Andrew Lyne and Gail Rynkowski and Andrew J. Cutler},
  journal={Journal of the American Academy of Child and Adolescent Psychiatry},
  year={2015},
  volume={54 11},
  pages={916-25.e2}
}
OBJECTIVE Despite the continuity of attention-deficit/hyperactivity disorder (ADHD) into adolescence, little is known regarding use of nonstimulants to treat ADHD in adolescents. This phase 3 trial evaluated the safety and efficacy of guanfacine extended release (GXR) in adolescents with ADHD. METHOD This 13-week, multicenter, randomized, double-blind, placebo-controlled trial evaluated once-daily GXR (1-7 mg per day) in adolescents with ADHD aged 13 to 17 years. The primary endpoint was the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 53 references

EPA-0685—Guanfacine XR (GXR) for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): phase 3, randomized, double-blind, multicenter, placeboand active-reference study

  • A Hervas, M Huss, M Johnson
  • Eur Psychiatry
  • 2014

Parenting stress in families of children with ADHD: a meta-analysis

  • J Theule, J Wiener, R Tannock, JM. Jenkins
  • J Emot Behav Disord
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…